Richardson D R, Baker E
Department of Physiology, University of Western Australia, Nedlands.
J Cell Physiol. 1994 Oct;161(1):160-8. doi: 10.1002/jcp.1041610119.
The mechanisms of iron (Fe) and transferrin (Tf) uptake by the human melanoma cell line, SK-MEL-28, have been investigated using chelators and metabolic probes. These data provide evidence for two saturable processes of Fe uptake from Tf, namely, specific receptor-mediated endocytosis and a second nonspecific, non-receptor-mediated mechanisms which saturated with respect to Fe uptake at a Tf concentration of approximately 0.3 mg/ml. In contrast to Fe uptake, Tf uptake increased linearly up to at least 1 mg/ml. Furthermore, under the culture conditions used, the second nonspecific, non-receptor-mediated mechanism was the most important process in terms of quantitative Fe uptake. Two concentrations of Tf-125I-59Fe (0.01 and 0.1 mg/ml) were used in order to characterise the specific and nonspecific Fe uptake pathways. Membrane permeable chelators were equally effective at both Tf concentrations, whereas membrane impermeable chelators were significantly (P < 0.001) more effective at reducing the internalisation of Fe at the higher Tf concentration, consistent with a mechanism of Fe uptake which occurred at a site in contact with the extracellular medium. The oxidoreductase inhibitor, amiloride, only slightly inhibited Fe uptake at the higher Tf concentration, suggesting that the second nonspecific process was not mediated by a diferric Tf reductase. Three lysosomotrophic agents and the endocytosis inhibitor, phenylglyoxal, markedly reduced Fe uptake at both Tf concentrations, and it is concluded that a saturable process consistent with receptor-mediated endocytosis of Tf occurred at the lower Tf concentration, while the predominant mechanism of Fe uptake at high Tf concentrations was a second saturable process consistent with adsorptive pinocytosis.
利用螯合剂和代谢探针,对人黑色素瘤细胞系SK - MEL - 28摄取铁(Fe)和转铁蛋白(Tf)的机制进行了研究。这些数据为铁从转铁蛋白摄取的两个可饱和过程提供了证据,即特异性受体介导的内吞作用和第二个非特异性、非受体介导的机制,后者在转铁蛋白浓度约为0.3 mg/ml时铁摄取达到饱和。与铁摄取不同,转铁蛋白摄取至少在1 mg/ml时呈线性增加。此外,在所使用的培养条件下,就铁摄取量而言,第二个非特异性、非受体介导的机制是最重要的过程。使用两种浓度的Tf - 125I - 59Fe(0.01和0.1 mg/ml)来表征特异性和非特异性铁摄取途径。膜可渗透的螯合剂在两种转铁蛋白浓度下效果相同,而膜不可渗透的螯合剂在较高转铁蛋白浓度下显著(P < 0.001)更有效地减少铁的内化,这与铁摄取发生在与细胞外介质接触部位的机制一致。氧化还原酶抑制剂阿米洛利在较高转铁蛋白浓度下仅轻微抑制铁摄取,表明第二个非特异性过程不是由双铁转铁蛋白还原酶介导的。三种溶酶体营养剂和内吞作用抑制剂苯乙二醛在两种转铁蛋白浓度下均显著降低铁摄取,得出的结论是,在较低转铁蛋白浓度下发生了与转铁蛋白受体介导的内吞作用一致的可饱和过程,而在高转铁蛋白浓度下铁摄取的主要机制是与吸附性胞饮作用一致的第二个可饱和过程。